Urelumab (** Generic name only (investigational drug - no approved brand names currently available) **)

Immunotherapy

1 Clinical Trials

Description

Urelumab is an investigational immunotherapy drug currently being studied by Bristol-Myers Squibb. It is designed to help the body's own immune system fight cancer. In clinical trials for colorectal cancer (CRC), Urelumab has been tested in combination with Cetuximab, a targeted therapy commonly used for certain types of CRC. The goal of these early-phase trials (Phase 1) is primarily to assess the safety and tolerability of the combination and to find the highest dose of Urelumab that can be given safely with Cetuximab. These trials help researchers understand how patients respond to the drug combination and identify potential side effects before moving to larger studies that test effectiveness.

Mechanism of Action

Urelumab is an immunotherapy agent. It works by targeting a specific protein on immune cells, which helps to boost the immune system's ability to recognize and attack cancer cells. By enhancing the immune response against the tumor, Urelumab aims to help control or eliminate the cancer. The specific protein targeted by Urelumab is being characterized in clinical trials.

Side Effects

As Urelumab is an investigational drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of these early trials is safety. Common side effects observed in early immunotherapy trials can include fatigue Skin reactions (like rash or itching) Diarrhea Nausea And changes in liver function. Side effects specific to the combination of Urelumab and Cetuximab are also being closely monitored. More detailed information on side effects will become available as clinical trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02110082 Phase 1
Archived
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
United States

Quick Info

Brand Name** Generic name only (investigational drug - no approved brand names currently available) **
CategoryImmunotherapy
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Bevacizumab
Immunotherapy
512 trials
Cetuximab
Immunotherapy
364 trials
Pembrolizumab
Immunotherapy
196 trials
Panitumumab
Immunotherapy
126 trials
Nivolumab
Immunotherapy
116 trials
Tislelizumab
Immunotherapy
62 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.